Zelgen Biopharma's Flunotinib Nominated for Breakthrough Therapy Designation; IPO Filing Submitted

▎Armstrong

On January 15, 2026, Zenitar's Furotinib Maleate Tablets are proposed to be included in the Breakthrough Therapy Drug Program for the treatment of BCR-ABL fusion gene (Ph)-negative myeloproliferative neoplasms.

Flunotinib is the core pipeline of Zenitar, currently in phase III clinical stage.

Flunotinib is aJAK2/FLT3/CDK6 Triple-Target Inhibitor.

Recently, Zenitar's Hong Kong IPO application has been accepted.

Since its establishment, Zenitar has undergone multiple rounds of financing, completing a C-round financing of 511 million yuan in November 2025, with a post-investment valuation of 3.411 billion yuan.

The latest equity structure of Zenitar is as follows: Qiming Venture Capital holds 12.0%, Sichuan Development holds 6.4%, Tencent holds 8.8%, Chengdu Sci-Tech Investment holds 4.3%, Prestige holds 3.7%, J&Z Capital holds 2.7%, Transthermo Life Sciences holds 2.4%, New Alliance Capital holds 2.4%, Guosheng Capital holds 2.2%, BlueRun Ventures holds 2.1%, Cowin Capital holds 2.1%, and Chuan Venture Capital holds 2.0%.

Summary

Flunotinib has undergone differentiated optimization under the guidance of rational design and has been translated into breakthrough clinical efficacy, offering the potential for better treatment options for myeloproliferative neoplasms and reshaping the clinical landscape. In addition, flunotinib is also exploring indications such as polycythemia vera, with expectations for its subsequent clinical progress.